Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

This study has been completed.
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Information provided by (Responsible Party):
Pfizer Identifier:
First received: May 10, 2011
Last updated: September 26, 2014
Last verified: September 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2014
  Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)